NasdaqGM:AXSMPharmaceuticals
What Axsome Therapeutics (AXSM)'s SUNOSI Patent Settlements and Migraine Updates Mean For Shareholders
Axsome Therapeutics recently resolved all U.S. patent litigation over its wake-promoting drug SUNOSI, entering settlements that allow five generic manufacturers to launch versions no earlier than March 1, 2040 (or September 1, 2040 with pediatric exclusivity), subject to regulatory approvals and customary conditions.
This long-dated patent clarity for SUNOSI, combined with fresh Phase 3 data and upcoming conference highlights for SYMBRAVO, materially clarifies Axsome’s product durability and...